Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study.
| Autor: | Rimassa, Lorenza, Li, Daneng, Ikeda, Masafumi, Yarchoan, Mark, Ryoo, Baek-Yeol, Kossler, Thibaud, Lim, Ho-Yeong, Kwiatkowski, Mariusz, Chang, Ting-Tsung, Kim, Jee Hyun, Casadei-Gardini, Andrea, Kudo, Masatoshi, Ren, Zhenggang, Varela Calvo, Maria, Llovet, Josep M, Zhang, Yayan, Hatogai, Ken, Siegel, Abby B., Cheng, Ann-Lii |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p484-484, 151p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|